Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

The rise in use of GLP-1 medications is driving a convergence between pharmaceutical therapies and consumer health and ...

Creating and bringing new medicines to patients is a uniquely complicated process. It requires robust scientific research, business acumen, tremendous financial investment, and patience — even when ...

On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, ...

GenVoy-ILM™ T cell Kit for mRNA is a lipid nanoparticle (LNP) reagent mix optimized for the delivery of mRNA or CRISPR Cas9 mRNA with gRNA into human primary T cells using LNPs prepared on the ...